Search
Search Results
##search.searchResults.foundPlural##
-
DISTRIBUTION OF DNA DAMAGE REPAIR GENE POLYMORPHISM hOGG1, XRCC1 and p53 AMONG SICKLE CELL DISEASE PATIENTS IN INDIA
1444PDF: 754HTML: 1458Table Genotype and allele frequencies of hOGG1 codon 326 Ser>Cys and p53 72Arg>Pro polymorphisms among SCD patients and control group: 159 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2703PDF: 810HTML: 6491Untitled: 204Untitled: 167Untitled: 163Untitled: 186 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
1818PDF: 813HTML: 1213 -
DNA Repair Genes and Chronic Myeloid Leukemia: XPD (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (1394) Gene Polymorphisms Polymorphisms of DNA Repair Genes in CML
1023PDF: 374HTML: 213 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1214PDF: 764HTML: 110 -
THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES Gene therapy for Hemoglobinopathies.
1960PDF: 1154Html: 254 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1189PDF: 449HTML: 18539Figure 1: 151Figure 2: 132Figure 3: 152Figure 4: 185Figure 5: 153 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
1956PDF: 1567HTML: 344 -
-
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2122PDF: 763HTML: 1603Figure 1: 159Table 1: 184 -
-
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2716PDF: 970HTML: 5494 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
942PDF: 1067Suppl. Files: 548HTML: 71 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1211PDF: 1127HTML: 419 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1091PDF: 996HTML: 171 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
1399PDF: 496HTML: 232 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1518PDF: 1124HTML: 176 -
OUTLINE OF IRON METABOLISM, WITH EMPHASIS TO ERYTHROID CELLS iron Metabolism
1638PDF: 797Html: 267 -
HEPATITIS C VIRUS INFECTION AND LYMPHOMA
914PDF: 509HTML: 7793 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3485PDF: 830HTML: 6692 -
IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA
2474PDF: 1076HTML: 120 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1127PDF: 705HTML: 1326Figure 1: 153Figure 2: 150 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3120PDF: 898HTML: 2922 -
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA
1610PDF: 621HTML: 2412 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4103PDF: 1485HTML: 419 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
2961PDF: 827HTML: 7148Kost Fig1: 163Kost Fig 2: 153Kost Fig3: 149Kost Fig 4: 166Kost Fig5: 162Kost fig 6: 149 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2169PDF: 851HTML: 1975Fig 1 Rossi: 151 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
2523PDF: 1026HTML: 94 -
APLASTIC ANEMIA AND VIRAL HEPATITIS
1210PDF: 512HTML: 22989 -
miR-155-5p PROMOTES CD34+ APOPTOSIS AND INHIBITS BONE MARROW HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY RAC1/CREB/MIR-15B AXIS
653PDF: 782PDF Supp. Files: 68HTML: 169 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1660PDF: 540HTML: 255 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1509PDF: 772HTML: 136 -
HIGHLIGHTS ON THE CONTRIBUTION OF GUT MICROBIOTA TO IMMUNE-MEDIATED DISEASES IN CHILDHOOD Gut microbiota in childhood immune-mediated diseases
843PDF: 409HTML: 61 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
4222PDF: 1444HTML: 1528Untitled: 207 -
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277505PDF: 1740HTML: 3835 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2056PDF: 1509HTML: 247 -
AN INEXPENSIVE CLINICAL-LABORATORY NOMOGRAM TO PREDICT POST-TREATMENT LUNG DESTRUCTION IN PULMONARY TUBERCULOSIS
435PDF: 176Suppl. Files: 41Html: 29 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
1938PDF: 1442HTML: 255
1 - 48 of 48 items







